Related references
Note: Only part of the references are listed.A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis
Christina A. Muzny et al.
SEXUALLY TRANSMITTED DISEASES (2020)
Secnidazole, an Approved Single Dose Drug for Bacterial Vaginosis, Does Not Cause Reproductive Toxicity in Animals [16A]
Helen Pentikis et al.
OBSTETRICS AND GYNECOLOGY (2020)
In vitro metabolic profile and drug-drug interaction assessment of secnidazole, a high-dose 5-nitroimidazole antibiotic for the treatment of bacterial vaginosis
Helen S. Pentikis et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Vaginitis in Nonpregnant Patients
Catherine M. Leclair
OBSTETRICS AND GYNECOLOGY (2020)
Prevalence of Trichomonas vaginalis Among Civilian, Noninstitutionalized Male and Female Population Aged 14 to 59 Years: United States, 2013 to 2016
Elaine W. Flagg et al.
SEXUALLY TRANSMITTED DISEASES (2019)
Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing
Megan Clare Craig-Kuhn et al.
SEXUALLY TRANSMITTED DISEASES (2019)
Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment
Paul Nyirjesy et al.
FUTURE MICROBIOLOGY (2018)
Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions
Helen S. Pentikis et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis
Jane R. Schwebke et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2017)
Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure
Ewelina Mielczarek et al.
INFECTION (2016)
Trichomonas vaginalis as a Cause of Perinatal Morbidity: A Systematic Review and Meta-Analysis
Bronwyn J. Silver et al.
SEXUALLY TRANSMITTED DISEASES (2014)
Diagnostic Rates Differ on the Basis of the Number of Read Days with the Use of the InPouch Culture System for Trichomonas vaginalis Screening
Charles. A. Rivers et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Mixed Vaginitis-More Than Coinfection and With Therapeutic Implications
Jack D. Sobel et al.
CURRENT INFECTIOUS DISEASE REPORTS (2013)
A Randomized Treatment Trial: Single Versus 7-Day Dose of Metronidazole for The Treatment of Trichomonas Vaginalis Among HIV-Infected Women
Patricia Kissinger et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004
Madeline Sutton et al.
CLINICAL INFECTIOUS DISEASES (2007)
Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition
R. Scott McClelland et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Personal digital assistants used to document compliance of bacterial vaginosis treatment
JB Bartley et al.
SEXUALLY TRANSMITTED DISEASES (2004)
Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts
P Moodley et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.
MA Klebanoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
